Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Return on Capital Employed for 12 consecutive years, with 0.3% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 26.0% to 0.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.3%, a 26.0% increase, with the full-year FY2025 number at 0.36%, up 38.0% from a year prior.
  • Return on Capital Employed was 0.3% for Q4 2025 at Madrigal Pharmaceuticals, up from 0.39% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.3% in Q4 2025 to a low of 3.08% in Q3 2022.
  • A 5-year average of 1.11% and a median of 0.93% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: plummeted -212bps in 2022, then surged 144bps in 2024.
  • Madrigal Pharmaceuticals' Return on Capital Employed stood at 1.14% in 2021, then tumbled by -78bps to 2.03% in 2022, then soared by 42bps to 1.19% in 2023, then surged by 53bps to 0.56% in 2024, then skyrocketed by 46bps to 0.3% in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Return on Capital Employed are 0.3% (Q4 2025), 0.39% (Q3 2025), and 0.38% (Q2 2025).